Prostate Cancer Clinical Trial
Official title:
Prognostic Value of SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma
Prognostic interest of bone scintigraphy in bone metastatic prostate carcinoma (BMPC) has been shown. Recent technological advances allow to perform quantitative bone SPECT-CT in routine practice. The aim of this study is to assess the prognostic interest of quantitative bone SPECT-CT in BMPC.
Prostate adenocarcinoma is one of the most common cancer in men, and bone its most frequent
distant metastasis location. 5-year survival has greatly increased these last two decades,
with wide differences between countries. Nevertheless, the prognosis of castrate-resistant
bone metastatic prostate cancer (BMPC) remains poor.
PCWG (Prostate Cancer Working Group) 2 has proposed in 2007 criteria to evaluate response to
treatment for prostate cancer. There are based on composite data, including clinical signs
(such as general condition and bone pain), Prostatic Specific Antigen (PSA) variation, CT
scan (RECIST criteria) and bone scan. The scintigraphic part is based on whole body planar
acquisition, and on the assessment of new uptakes. These bone scan criteria are simplistic,
because only a visual analysis is possible, without consideration of changes in intensity.
Moreover, these criteria consider the bone scan as a planar imaging, and it has been shown
that Single Photon Emission Computed Tomography (SPECT) improved sensitivity, specificity,
positive and negative predictive values in oncologic context. Finally, "PCWG2 (Prostate
Cancer Working Group 2) recognizes that there are no validated criteria for response on
radionuclide bone scan".
To reflect bone metastasis burden, a quantitative analysis method for bone scintigraphy, the
Bone Scan Index (BSI), had been tested. BSI is based on the uptake of whole body planar
imaging. While baseline BSI seemed to offer a poor correlation with overall survival (OS),
on-treatment changes in BSI appeared to be a decent response marker. But a volumetric
quantitative biomarker may improve the accuracy of this assessment.
The recent development of a new SPECT quantification tool (xSPECT Quant® tool, Siemens) could
offer good performances on therapeutic assessment. The objective of this study is to assess
the interest of this new quantitative volumetric method in bone scan response evaluation of
BMPC.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
| Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
| Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
| Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
| Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
| Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
| Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
| Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
| Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |